Marketing-authorisation holder
Citius Pharms
2 medicines in 1 country, as authorisation holder.
Medicines
Every medicine in the registers under its name, current ones first.
2 medicines
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| LYMPHIR300mcg · Injectable | Denileukin diftitox | United States | Marketed | 2024 |
| SUPRENZA15MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | 30MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | 37.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · Tablet, orally disintegrating | Phentermine | United States | Not marketed | 2012 |
Countries
Where it holds or makes medicines, with how many are current.
| Country | Medicines | Current | Past | Companies |
|---|---|---|---|---|
| United States | 2 | 2 | 0 | CompaniesAll medicines |
Top substances
At a glance
- Type
- Marketing-authorisation holder
- Medicines
- 2
- Countries
- 1
- Roles
- Authorisation holder
Work with Prognia
Keep Citius Pharms’s medicines accurate on Prognia, see how professionals use them and answer what they ask. A 20-minute call, in English.
Book a call